Login
Navigate Fool.com
Will ELN beat
the market?

Elan

NYSE: ELN

Community Rating: 3 Stars: Appealing

12.36 0.32 (2.66%)

REAL-TIME: Last trade at

Extended Hours: $12.36 $0.00 (0.00%)
Quote as of (NYSE)


company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $12.15
Previous Close $12.04
Daily Range $12.15 - $12.42
52-Week Range $9.37 - $14.91
Market Cap $7.4B
P/E Ratio -19.11
Dividend (Yield) $0.00 (0.0%)
Volume 30,236,658
Average Daily Volume 8,038,283
Current FY EPS $0.11

How do you think ELN
will perform against the market?

Top ELN Bull/Bear Pitches

 

rainmaker59 (< 20)
Submitted November 12, 2009

Rulebreaker pick of Jan. 2009. All debt is related to massive R&D expenses. Leading edge of RX for Crohn's, MS and Alzheimer's.

1 Replies Reply Report this Post
 

michjksn (0)
Submitted February 27, 2009

Historically poorly run company. One product which causes death all too often/terrible press. No products on horizon, including Bap, worth anything other than being money pits for underachievement. … More

0 Replies Reply Report this Post

News & Commentary

When Savvy Dealmaking Borders on Reckless Spending

Is Elan deftly making deals or blowing its newfound cash hoard?

Elan Announces Pricing of US$850 Million in Aggregate Principal Amount of Senior Notes Due 2021

Elan Rejects Latest Royalty Pharma Approach

Elan Corporation, plc’s Board of Directors Unanimously Reject Royalty Pharma’s Revised Tender Offer

Royalty Pharma Lowers Acceptance Threshold For Elan Offer

Value Investor Seth Klarman's Shakeups

Flush With Cash, Elan Goes on a Buying Spree

Elan Proposes Sweeping Transformation

The company aims to make a raft of acquisitions.

Biotech Companies: The FDA Doesn't Care About Your Phase 3 Trials

Results? Yes. Starting them? Not so much.

Royalty Pharma Raises Takeover Bid for Elan

See More ELN News...

Sector

Healthcare

Industry

Drugs

Elan (ELN) Description

The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry. Website: http://www.elan.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks